Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Centaur Media sells The Lawyer for £43m

(Sharecast News) - Business information and marketing provider Centaur Media said on Thursday that it has signed a sale and purchase agreement with Lighthouse Bidco, the parent company of Legal Benchmarking, for the sale of thelawyer.com, the operating company of The Lawyer. Centaur Media said the Lawyer had been sold for an enterprise value of £43m, representing a multiple of 16x FY24 operating profit, calculated on a cash-free, debt-free basis, subject to customary adjustments in respect of working capital and cash profits to completion.

The London-listed firm stated the sale would unlock "significant shareholder value" and provide cash to the group for the benefit of all stakeholders. On receipt of the net proceeds, Centaur intends to consult shareholders on the approach to return cash. As at the close of business on 9 September, Centaur had net cash of £24.5m.

Completion was expected to occur around the start of October.

Chairman Martin Rowland said: "Today's announcement represents a further significant milestone in Centaur's pursuit to maximise shareholder value. The Transaction follows the sale of MiniMBA which completed on 18 July 2025 and the previously announced review of the group's operations and strategy with a fundamental part of this review being to address the board's desire to realise Centaur's potential and to maximise shareholder value"

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.